

thermo**scientific**

Do you want to
refine your view?

B·R·A·H·M·S CgA II KRYPTOR
as new opportunity in prostate cancer!

ThermoFisher
SCIENTIFIC

Prostate cancer:

Relevant for lives, important to have on screen


Most prevalent cancer

in men worldwide

Standard therapeutic approaches (depending on disease status):

- Watchful Waiting
- Chemo-/Radiotherapy/Surgery
- Hormonal therapy/Androgen Deprivation Therapy (ADT)

Other cancers
11 059 696 (52.6%)



Number of prevalent cancer cases in 2018, male, all age¹

Neuroendocrine prostate cancer

Neuroendocrine prostate cancer (NEPC) is an aggressive subtype of prostate cancer characterized by neuroendocrine differentiated cells.

When progressing up to **40 %** of PCs develop neuroendocrine differentiation (NED).²

Prostate cells are stimulated by androgens.

ADTs target androgen receptor signaling and thus suppress proliferation. (chemical castration)

ADT promotes development of NEPC by neuroendocrine differentiation.

NEPC can proliferate independently from androgen receptor signalling and is usually resistant to ADT (Castration resistant prostate cancer = CRPC).

For CRPC a change of therapy is necessary.

Monitoring is necessary to detect:


- **Neuroendocrine differentiation**
- **Treatment-emergent resistance to ADT**
- **Risk of progression**




Chromogranin A

A sensitive marker in blood serum

- Glycoprotein with a molecular weight of 49kDA
- Produced as a precursor of a wide range of different hormones in neuroendocrine cells
- Secreted from neuroendocrine cells into the blood
- Therefore increasingly important as a marker for tumors with neuroendocrine characteristics
- Serves as a progression parameter



Neuroendocrine prostate cancer cells usually do not secrete PSA but CgA, and thus NEPC patients often show disproportionately low PSA values and CgA is elevated.³



Cumulated ratio of patients with elevated CgA levels depending on time under ADT treatment⁴


Experts recommend measurement of serum CgA levels in 3-month intervals in patients under hormonal treatment.⁴

B·R·A·H·M·S CgA II KRYPTOR:

Complementary detection tool in prostate cancer


Documented utility of circulating CgA in NEPC

Studies have shown:




Useful in all spots of therapy route

Focus on follow-up of patients under ADT (incl. Abiraterone^{9,10})



* ~ 50 % of patients receiving ADT¹¹ (alone or in combination)



Advantages of Thermo Scientific™ B·R·A·H·M·S™ CgA II KRYPTOR™ in prostate cancer:

- **Earlier change of therapy by early identification of neuroendocrine differentiation and related ADT resistance**
- **More confidence in follow-up**
- **Better patient care**



B·R·A·H·M·S CgA II KRYPTOR

The automated immunoassay for Chromogranin A is not only indicated in neuroendocrine tumors but also provides a tool to aid in the early identification of neuroendocrine differentiated prostate cancer and related ADT resistance.

- more safety for the patient
- earlier change of therapy
- more confidence in follow-up

Refine your view in prostate cancer – NOW!



Use serum CgA as a tool in early detection of prostate cancer transition during monitoring of all your patients under hormonal treatment.

References:

1. Bray, F., et al., CA Cancer J Clin, 2018. 68(6): p. 394–424.
2. Tritschler, S., et al., Pathologie, 2018. 39(4): p. 333–343.
3. Beltran, H., et al., Cancer Discov, 2011. 1(6): p. 487–95.
4. Tarle, M., M.Z. Ahel, and K. Kovacic, Anticancer Res, 2002. 22(4): p. 2525–9.
5. Berruti, A., et al., J Urol, 2007. 178(3 Pt 1): p. 838-43; quiz 1129.
6. Aggarwal, R.R., F.Y. Feng, and E.J. Small, Oncology (Williston Park), 2017. 31(6): p. 467–74.
7. Hirano, D., et al., Scand J Urol Nephrol, 2007. 41(4): p. 297–301.2.
8. Sciarra, A., et al., Urol Int, 2009. 82(2): p. 147–51.
9. Dong, B., et al., Prostate, 2017. 77(13): p. 1373–1380.
10. Fan, L., et al., BJU Int, 2017. 120(2): p. 226–232.
11. Liede, A., et al., ESMO Open, 2016. 1(2): p. e000040.

Clinical Diagnostics	Thermo Fisher Scientific B-R-A-H-M-S GmbH Neuendorfstr. 25 16761 Hennigsdorf Germany	+49 (0)3302 883 0 +49 (0)3302 883 100 fax info.onco@thermofisher.com www.thermoscientific.com/brahms
-----------------------------	--	---

Find out more at thermofisher.com/brahms

Products are CE marked but not 510(k)-cleared and not available for sale in the U.S. Availability of products in each country depends on local regulatory marketing authorization status.

©2020 Thermo Fisher Scientific Inc. All rights reserved. All trademarks are the property of Thermo Fisher Scientific and its subsidiaries unless otherwise specified. KRYPTOR is trademark of Cisbio Bioassays, licensed for use by B-R-A-H-M-S GmbH, a part of Thermo Fisher Scientific. Nobel Prize is a registered trademark of the Nobel Foundation.

107726.1

ThermoFisher
SCIENTIFIC